Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFMW) Gross Margin (2018 - 2025)

Historic Gross Margin for Sunshine Biopharma (SBFMW) over the last 8 years, with Q3 2025 value amounting to 32.64%.

  • Sunshine Biopharma's Gross Margin fell 13400.0% to 32.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.01%, marking a year-over-year increase of 22300.0%. This contributed to the annual value of 30.6% for FY2024, which is 40200.0% down from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Gross Margin is 32.64%, which was down 13400.0% from 36.37% recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Gross Margin ranged from a high of 64.98% in Q2 2021 and a low of 25.33% during Q2 2024
  • Over the past 5 years, Sunshine Biopharma's median Gross Margin value was 35.12% (recorded in 2023), while the average stood at 39.98%.
  • In the last 5 years, Sunshine Biopharma's Gross Margin plummeted by -346500bps in 2021 and then soared by 110500bps in 2025.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Gross Margin stood at 28.0% in 2021, then skyrocketed by 35bps to 37.85% in 2022, then dropped by -12bps to 33.44% in 2023, then dropped by -4bps to 32.24% in 2024, then grew by 1bps to 32.64% in 2025.
  • Its Gross Margin was 32.64% in Q3 2025, compared to 36.37% in Q2 2025 and 30.67% in Q1 2025.